People: Pacira Pharmaceuticals Inc (PCRX.O)

PCRX.O on Nasdaq

86.46USD
11 Jul 2014
Price Change (% chg)

$0.94 (+1.10%)
Prev Close
$85.52
Open
$86.02
Day's High
$87.30
Day's Low
$84.84
Volume
397,236
Avg. Vol
502,770
52-wk High
$94.30
52-wk Low
$30.55

Search Stocks

Hastings, Paul 

Brief Biography

Mr. Paul J. Hastings is an Independent Director of Pacira Pharmaceuticals Inc. Mr. Hastings has been the president and chief executive officer of OncoMed Pharmaceuticals, Inc. since January 2006. Prior to joining OncoMed, Mr. Hastings was president and chief executive officer of QLT, Inc. Before this role, Mr. Hastings served as president and chief executive officer of Axys Pharmaceuticals, Inc., which was acquired by Celera Corporation in 2001. Prior to Axys, Mr. Hastings was president of Chiron Biopharmaceuticals and also held a variety of management positions of increasing responsibility at Genzyme Corporation, including president of Genzyme Therapeutics Europe and president of Worldwide Therapeutics. Mr. Hastings was Chairman of the Board of Proteolix (sold to Onyx) and was a member of the board of directors of ViaCell Inc. (sold to Perkin Elmer). Mr. Hastings currently serves on the board of directors of Relypsa Inc., a clinical-stage biopharmaceutical company, and the Bay Area Biosciences Association (Bay Bio), and he is Chair of the Emerging Companies Section of the Biotechnology Industry Organization. He received a Bachelor of Science degree in pharmacy from the University of Rhode Island.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

David Stack

918,972

James Scibetta

469,030

Taunia Markvicka

459,530

Gary Patou

367,600

Laura Brege

--

Yvonne Greenstreet

--
As Of 30 Dec 2013
Search Stocks